Barclays’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,000
| Closed | -$2.14M | – | 5507 |
|
|
2024
Q4 | $2.14M | Sell |
3,000
-600
| -17% | -$504K | ﹤0.01% | 2829 |
|
|
2024
Q3 | $3.78M | Buy |
+3,600
| New | +$4.01M | ﹤0.01% | 2318 |
|
|
2022
Q3 | – | Sell |
-44,500
| Closed | -$26.3M | – | 5075 |
|
|
2022
Q2 | $26.3M | Buy |
+44,500
| New | +$28.9M | 0.02% | 600 |
|
|
2021
Q2 | – | Sell |
-30,000
| Closed | -$14.2M | – | 5048 |
|
|
2021
Q1 | $14.2M | Buy |
30,000
+20,800
| +226% | +$10.1M | 0.01% | 936 |
|
|
2020
Q4 | $4.44M | Buy |
9,200
+2,800
| +44% | +$1.51M | ﹤0.01% | 1597 |
|
|
2020
Q3 | $3.58M | Sell |
6,400
-2,200
| -26% | -$1.33M | ﹤0.01% | 1635 |
|
|
2020
Q2 | $5.36M | Sell |
8,600
-20,800
| -71% | -$11.8M | ﹤0.01% | 1328 |
|
|
2020
Q1 | $14.4M | Sell |
29,400
-27,400
| -48% | -$11.3M | 0.01% | 800 |
|
|
2019
Q4 | $21.3M | Buy |
56,800
+17,900
| +46% | +$6.02M | 0.01% | 925 |
|
|
2019
Q3 | $10.8M | Sell |
38,900
-18,300
| -32% | -$5.42M | 0.01% | 1237 |
|
|
2019
Q2 | $17.9M | Sell |
57,200
-33,200
| -37% | -$11.1M | 0.01% | 994 |
|
|
2019
Q1 | $37.1M | Buy |
90,400
+35,000
| +63% | +$14.4M | 0.03% | 540 |
|
|
2018
Q4 | $20.7M | Sell |
55,400
-11,700
| -17% | -$4.28M | 0.02% | 730 |
|
|
2018
Q3 | $27.1M | Sell |
67,100
-54,500
| -45% | -$20.7M | 0.02% | 701 |
|
|
2018
Q2 | $42M | Buy |
121,600
+5,100
| +4% | +$1.6M | 0.04% | 430 |
|
|
2018
Q1 | $40.1M | Sell |
116,500
-7,800
| -6% | -$2.71M | 0.03% | 513 |
|
|
2017
Q4 | $46.7M | Buy |
124,300
+30,500
| +33% | +$12.4M | 0.04% | 443 |
|
|
2017
Q3 | $41.9M | Sell |
93,800
-191,000
| -67% | -$90.9M | 0.04% | 364 |
|
|
2017
Q2 | $140M | Buy |
284,800
+181,600
| +176% | +$79.5M | 0.15% | 103 |
|
|
2017
Q1 | $40M | Buy |
103,200
+43,900
| +74% | +$16.3M | 0.04% | 313 |
|
|
2016
Q4 | $21.8M | Sell |
59,300
-4,900
| -8% | -$1.86M | 0.02% | 555 |
|
|
2016
Q3 | $25.8M | Sell |
64,200
-10,800
| -14% | -$4.33M | 0.03% | 441 |
|
|
2016
Q2 | $26.2M | Buy |
75,000
+17,800
| +31% | +$6.86M | 0.03% | 413 |
|
|
2016
Q1 | $20.6M | Sell |
57,200
-40,400
| -41% | -$16.6M | 0.03% | 464 |
|
|
2015
Q4 | $52.9M | Sell |
97,600
-51,900
| -35% | -$28.1M | 0.06% | 266 |
|
|
2015
Q3 | $69.5M | Sell |
149,500
-53,200
| -26% | -$28.6M | 0.08% | 204 |
|
|
2015
Q2 | $103M | Sell |
202,700
-20,700
| -9% | -$10.1M | 0.12% | 142 |
|
|
2015
Q1 | $101M | Buy |
223,400
+92,800
| +71% | +$39.3M | 0.12% | 156 |
|
|
2014
Q4 | $53.5M | Sell |
130,600
-42,600
| -25% | -$16.8M | 0.05% | 330 |
|
|
2014
Q3 | $62.4M | Buy |
173,200
+119,400
| +222% | +$40M | 0.06% | 259 |
|
|
2014
Q2 | $15.2M | Sell |
53,800
-5,300
| -9% | -$1.57M | 0.02% | 861 |
|
|
2014
Q1 | $17.7M | Buy |
59,100
+18,200
| +44% | +$5.61M | 0.02% | 766 |
|
|
2013
Q4 | $11.2M | Sell |
40,900
-27,200
| -40% | -$7.82M | 0.01% | 1163 |
|
|
2013
Q3 | $21.2M | Sell |
68,100
-32,600
| -32% | -$8.57M | 0.03% | 637 |
|
|
2013
Q2 | $22.6M | Buy |
+100,700
| New | +$23.4M | 0.03% | 588 |
|
Other funds holding REGN
VCM
N
Barclays's REGN Position: Q1 2026 in Review
Barclays increased its Regeneron Pharmaceuticals (REGN) stake by 0.62% in Q1 2026, buying an estimated $1.47M and bringing the position to 313,093 shares worth $242M. The position accounts for 0.06% of the portfolio, ranked #247.
Barclays first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $434M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Barclays held 313,093 shares of Regeneron Pharmaceuticals worth $242M as of Q1 2026.
- Barclays bought 1,926 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.47M.
- Regeneron Pharmaceuticals made up 0.06% of Barclays's portfolio in Q1 2026, its #247 holding.
- Barclays first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Regeneron Pharmaceuticals position peaked at $434M in Q3 2024.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.